Lucid Diagnostics (LUCD) AI Stock Analysis

• Market Cap: $144.57M
• Dividend Yield: N/A
• Average Volume (3M): 623.79K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.07
• Revenue Growth: 5.01%
• EPS Growth: 20.76%
• Country: US
• Employees: 72
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.10
• Shares Outstanding: 137,683,000
• 10 Day Avg. Volume: 578,963
• 30 Day Avg. Volume: 623,794
• PEG Ratio: 0.05
• Price to Book (P/B): 7.67
• Price to Sales (P/S): 9.52
• P/FCF Ratio: -0.92
• Enterprise Value/Market Cap: 0.97
• Enterprise Value/Revenue: 0.12
• Enterprise Value/Gross Profit: -0.29
• Enterprise Value/Ebitda: -0.01
• 1Y Price Target: $4.05
• Price Target Upside: 224.00% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $1.00 ▼(-20.00% Downside)

Lucid Diagnostics faces significant financial challenges with negative margins and high leverage, impacting its overall score. While strategic initiatives and potential Medicare coverage offer future growth prospects, current financial instability and lack of profitability weigh heavily on the stock's evaluation.

Positive Factors

Medicare Coverage Progress

Securing Medicare coverage for EsoGuard could significantly increase revenue by expanding access to a large patient base, enhancing long-term growth prospects.

New Data on EsoGuard

The positive real-world data supports EsoGuard's utility as a non-invasive screening tool, potentially boosting adoption and market penetration.

Strengthened Financial Position

The strengthened financial position extends the company's runway through 2026, providing stability and resources for strategic initiatives.

Negative Factors

Negative Margins

Persistent negative margins indicate challenges in achieving profitability, which could hinder long-term financial health and investment appeal.

High Leverage

High leverage poses a risk to financial stability, potentially limiting the company's ability to invest in growth and weather economic downturns.

Cash Flow Issues

Ongoing cash flow issues could strain operations and limit the company's ability to fund growth initiatives, impacting long-term viability.

Lucid Diagnostics Business Overview & Revenue Model

Company Description

Lucid Diagnostics (LUCD) is a medical diagnostics company focused on developing and commercializing innovative solutions for the early detection and prevention of gastrointestinal diseases, particularly esophageal cancer. The company operates primarily in the healthcare sector, leveraging its proprietary technology to provide non-invasive diagnostic tests that aid physicians in identifying precancerous conditions. Its core product, the EsoGuard test, is designed to analyze cells from the esophagus to detect early signs of cancer and other related disorders, facilitating timely intervention and improving patient outcomes.

How the Company Makes Money

Lucid Diagnostics generates revenue primarily through the sale of its diagnostic tests, notably the EsoGuard test. The company operates a direct-to-consumer model as well as partnerships with healthcare providers, hospitals, and laboratories that utilize its testing services. Revenue is derived from test reimbursements through insurance companies and government programs, as well as out-of-pocket payments from patients. Additionally, Lucid Diagnostics may explore strategic partnerships with pharmaceutical companies and healthcare systems to expand its market reach and enhance its service offerings, which could further contribute to its revenue streams.

Lucid Diagnostics Financial Statement Overview

Summary

Lucid Diagnostics shows significant revenue growth, but negative margins and high leverage pose major concerns. The company struggles with profitability and cash flow, indicating weak financial health.

Income Statement

Lucid Diagnostics shows significant revenue growth in the TTM period, but this is overshadowed by negative margins across the board. The company struggles with profitability, as evidenced by negative gross, net, EBIT, and EBITDA margins. The high revenue growth rate is a positive sign, but the inability to convert this into profit is a major concern.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio, indicating significant leverage, which poses a risk. The negative return on equity suggests that the company is not generating returns for shareholders. The equity ratio is moderate, but overall, the financial stability is questionable due to high leverage and negative equity in some periods.

Cash Flow

Cash flow analysis shows negative operating and free cash flows, with a high free cash flow to net income ratio indicating cash flow issues. The company has not been able to generate positive cash flow, which is critical for sustaining operations and growth. The free cash flow growth rate is positive in the TTM period, but this is not enough to offset the overall negative cash flow situation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.21B	4.35M	2.43M	377.00K	500.00K	0.00
Gross Profit	-488.29M	-3.92M	-6.05M	-3.24M	-85.00K	0.00
EBITDA	-10.00B	-44.34M	-49.75M	-54.23M	-27.41M	482.00
Net Income	-10.44B	-45.53M	-52.67M	-56.17M	-28.08M	-8.28M
Balance Sheet
Total Assets	53.20M	30.71M	27.27M	32.51M	59.00M	2.19M
Cash, Cash Equivalents and Short-Term Investments	47.33M	22.36M	18.90M	22.47M	53.66M	111.00K
Total Debt	24.34M	21.25M	15.26M	2.00M	0.00	0.00
Total Liabilities	27.36M	25.32M	29.58M	9.46M	4.26M	15.71M
Stockholders Equity	25.84M	5.39M	-2.31M	23.05M	54.74M	-13.52M
Cash Flow
Free Cash Flow	-44.18M	-44.79M	-33.04M	-30.59M	-18.53M	-5.63M
Operating Cash Flow	-43.78M	-44.14M	-32.82M	-29.68M	-17.67M	-5.63M
Investing Cash Flow	-405.00K	-646.00K	-221.00K	-4.11M	-862.00K	0.00
Financing Cash Flow	77.03M	48.25M	29.46M	2.61M	72.08M	5.58M

Lucid Diagnostics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.25
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LUCD, the sentiment is Positive. The current price of 1.25 is above the 20-day moving average (MA) of 1.06, above the 50-day MA of 1.12, and above the 200-day MA of 1.20, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 58.43 is Neutral, neither overbought nor oversold. The STOCH value of 70.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LUCD.

Lucid Diagnostics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ICAD	60 Neutral	―	―	―	―	-4.15%	3.49%
XTNT	59 Neutral	$99.09M	72.55	3.64%	―	16.88%	―
OWLT	56 Neutral	$385.30M	―	―	―	26.83%	-52.47%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LUNG	51 Neutral	$70.08M	-1.20	-73.73%	―	15.59%	4.13%
LUCD	47 Neutral	$144.57M	―	-331.24%	―	5.01%	20.76%
RCEL	42 Neutral	$106.73M	―	-1746.27%	―	20.59%	18.61%

Lucid Diagnostics Corporate Events

Lucid Diagnostics Gains Medicare Support for EsoGuard

Lucid Diagnostics reported its third-quarter 2025 financial results, highlighting the processing of 2,841 EsoGuard tests and revenue of $1.2 million. The company ended the quarter with over $47 million in cash, extending its financial runway through 2026. A significant development was the unanimous expert consensus at the Multi-Jurisdictional Contractor Advisory Committee meeting supporting Medicare coverage for EsoGuard, marking a crucial step towards securing transformative Medicare coverage. The company also strengthened its market access team and announced upcoming initiatives, including a summit focused on cancer prevention in the fire service.

Lucid Diagnostics Appoints John R. Palumbo to Board

On September 25, 2025, Lucid Diagnostics announced the appointment of John R. Palumbo to its Board of Directors, effective September 22, 2025. Palumbo brings 40 years of healthcare leadership experience, including guiding early-stage companies through commercial growth. His appointment is expected to support Lucid’s strategic initiatives as it approaches key commercial milestones, particularly in addressing unmet needs in cancer prevention with its EsoGuard product.

Lucid Diagnostics Completes Public Offering for $26.9 Million

On September 11, 2025, Lucid Diagnostics Inc. announced the closing of its underwritten public offering of 28,750,000 shares of common stock at $1.00 per share, generating approximately $26.9 million in net proceeds. The funds are intended for working capital and general corporate purposes, with Canaccord Genuity LLC and BTIG, LLC acting as joint bookrunners, and Maxim Group LLC as co-manager. This offering, made under an existing shelf registration, aims to strengthen Lucid’s financial position and support its ongoing operations in the cancer prevention diagnostics market.

Lucid Diagnostics Announces Public Stock Offering

On September 10, 2025, Lucid Diagnostics entered into an underwriting agreement for a public offering of its common stock, pricing each share at $1.00. The offering, managed by Canaccord Genuity LLC and BTIG, LLC, aims to raise $25 million, with potential to increase to $28.75 million if additional shares are purchased. The proceeds will support working capital and general corporate purposes, with the sale expected to close on September 11, 2025, subject to customary conditions.